

Published in final edited form as:

Blood. 2011 February 3; 117(5): 1472–1482. doi:10.1182/blood-2010-08-270033.

How I treat essential thrombocythemia

Philip A. Beer^{1,3}, Wendy N. Erber^{2,3}, Peter J. Campbell^{3,4}, and Anthony R. Green^{1,3}

¹Cambridge Institute for Medical Research, University of Cambridge, Cambridge, United Kingdom

²Department of Haematology, University of Cambridge, Cambridge, United Kingdom

³Department of Haematology, Addenbrooke's Hospital, Cambridge, United Kingdom

⁴Wellcome Trust Sanger Institute, Hinxton, United Kingdom

Abstract

In the past 5 years we have witnessed significant advances in both the diagnostic process and optimal therapy for patients with essential thrombocythemia (ET). Insights into the underlying molecular mechanisms have been accompanied by the development of new diagnostic tests and by an improved understanding of the relationship between ET and other related myeloproliferative neoplasms, such as polycythemia vera and primary myelofibrosis. In the first part of this review, we describe how recent molecular and histologic studies can be integrated into a streamlined diagnostic process that is applicable to everyday clinical practice. We also address areas of current diagnostic controversy, including heterogeneity within ET and the phenotypic overlap between ET, polycythemia vera, and primary myelofibrosis. In the second part, we provide an overview of our current approach to the treatment of ET, including risk stratification, choice of cytoreductive agent, and a consideration of special situations such as the pregnant or perioperative patient. Areas of controversy discussed include the identification of those at high risk of complications and therapeutic decisions in the younger patient.

Introduction

Essential thrombocythemia (ET) is a clonal stem cell disorder that shares phenotypic and pathologic similarities with other myeloproliferative neoplasms (MPNs), particularly polycythemia vera (PV) and primary myelofibrosis (PMF). In the last 5 years there has been an acceleration in our understanding of these disorders, after the identification of an acquired *JAK2* V617F mutation in approximately 50% of ET patients, along with one-half of those with PMF and the majority with PV.^{1,2} Subsequently mutations in *MPL* were reported in approximately 4% of patients with ET or PMF,³⁻⁵ and mutations in *TET2* have been observed in a variety of myeloid malignancies, including *JAK2* V617F-positive and -negative ET.⁶ In this article, we explore the impact of recent molecular and therapeutic advances on the way we diagnose and manage patients with ET.

Copyright 2011 by The American Society of Hematology; all rights reserved.

Correspondence: Prof Tony Green, Cambridge Institute for Medical Research, Hills Rd, Cambridge CB2 0XY, United Kingdom; arg1000@cam.ac.uk. .

Authorship Contribution: P.A.B. and A.R.G. wrote the manuscript; P.J.C. contributed to the writing of the manuscript; W.N.E. contributed to the writing of the "How we diagnose ET" section; and all authors reviewed and revised the final manuscript.

Conflict-of-interest disclosure: The authors declare no competing financial interests.

How we diagnose ET

We consider a diagnosis of ET when there is an unexplained and persistent thrombocytosis (platelet count $> 450 \times 10^9/L$). ET has traditionally been a diagnosis of exclusion, requiring the absence of reactive conditions and other clonal disorders that may present with thrombocytosis (Table 1). The discovery of mutations in *JAK2* and *MPL* now allows for the positive identification of ET in more than one-half of all cases. In our practice, screening for the *JAK2* V617F mutation is the initial investigation performed in all patients with suspected ET, followed by screening for *MPL* exon 10 mutations in V617F-negative cases. *TET2* screening is not currently performed because mutations are present in a wide range of other myeloid malignancies,⁶ screening is not straightforward, and the prognostic significance of *TET2* mutations in ET is currently unknown.

In the presence of a pathogenetic mutation in *JAK2* or *MPL*, a diagnosis of ET requires exclusion of PV and PMF. To this end, we find blood film examination and assessment of iron status to be helpful. A normal hemoglobin count in an iron-replete patient is usually sufficient to exclude PV. Although reduced serum ferritin and/or absent bone marrow iron stores may occur in patients with ET,⁷ we consider the combination of microcytic red cells and a normal hemoglobin count in a *JAK2* V617F-positive white patient highly suggestive of iron-deficient PV. In our opinion, PMF can generally be excluded by the absence of significant splenomegaly, unexplained anemia, teardrop poikilocytes, and a leukoerythroblastic blood film. A minority of patients with chronic myelomonocytic leukemia harbor a *JAK2* V617F mutation, although such cases generally lack thrombocytosis, with additional features such as leukocytosis, monocytosis, and splenomegaly, suggesting the correct diagnosis.⁸

In patients with suspected ET who lack *JAK2* and *MPL* mutations, the exclusion of reactive causes is particularly important (Table 1). In studies of unselected patients with thrombocytosis, fewer than 20% harbored a clonal blood disorder.^{9,10} Therefore a careful history, assessment of inflammatory markers (C-reactive protein and/or erythrocyte sedimentation rate), and bone marrow histology are all recommended (Figure 1). Cytogenetic analysis may also be considered, and we use a panel of fluorescent in situ hybridization probes to detect MPN-associated chromosome abnormalities (detecting additional copies of chromosomes 8 and 9 and deletions of 20q and 13q). However, chromosomal lesions are present in only 5% of patients at diagnosis and lack prognostic significance.¹¹ In the absence of a molecular or cytogenetic marker of clonal hematopoiesis, ET remains a diagnosis of exclusion.

Diagnostic criteria for ET are presented in Table 2. Criteria from the British Committee for Standards in Haematology (BCSH)¹² are used in our clinic. These criteria are similar to those of the WHO¹³ but differ in 3 important respects. First, in the presence of a pathogenetic mutation a diagnosis of ET does not necessarily require bone marrow studies, as other myeloid disorders that present with thrombocytosis and a *JAK2* or *MPL* mutation can generally be excluded by clinical and laboratory features as outlined above. However, it is our practice to obtain bone marrow aspirate and trephine biopsy samples from most patients at diagnosis. This is to provide both confirmatory data (bone marrow generally showing normal cellularity in the presence of giant megakaryocytes with hyperlobated nuclei) and prognostic information, specifically the degree of reticulin fibrosis.¹¹ A bone marrow sample at diagnosis also provides a useful baseline for subsequent comparisons, for example, after myelofibrotic transformation. Second, BCSH criteria do not use bone marrow histology to subdivide ET into “true-ET” and “prefibrotic myelofibrosis” because the existence of the latter as a distinct entity remains controversial and the underlying histologic criteria are difficult to apply reproducibly.¹⁴ Third, the BCSH classification includes

patients with bone marrow reticulin greater than grade 2 (on a 0-4 scale) who lack other features of PMF or myelofibrotic transformation. Under current World Health Organization (WHO) criteria, such patients cannot be classified as either ET, because they have too much reticulin, or PMF, because they have none of the clinical features required for this diagnosis.

Myelofibrotic transformation of ET

Evolution to myelofibrosis affects a proportion of ET patients, although the reported prevalence varies widely, reflecting differences in study design, therapeutic intervention, and the diagnostic criteria applied. Retrospective studies suggest that myelofibrotic transformation increases with disease duration, affecting 3%-10% in the first decade after diagnosis and 6%-30% in the second decade.¹⁵⁻¹⁷ Given the close relationship of post-ET myelofibrosis to PMF, the criteria we use to diagnose these conditions are essentially the same (Table 3). These criteria are similar to other widely used systems^{13,18,19} but do not include serum lactate dehydrogenase (LDH) because a correlation between increasing LDH and myelofibrotic transformation has yet to be established and increased levels of LDH also are found in most patients with ET or PV.²⁰ It is important to emphasize that the development of reticulin fibrosis on its own does not equate to transformation to myelofibrosis, and the diagnosis of myelofibrotic transformation is reserved for those patients who demonstrate bone marrow fibrosis in association with accompanying clinical and/or laboratory features (Table 3).

Leukemic transformation of ET

Progression to acute myeloid leukemia (AML) occurs in a small minority of patients, with retrospective studies suggesting an incidence of 1%-2.5% in the first decade after diagnosis, 5%-8% in the second decade, and continuing to increase thereafter.^{15,16,21} However, studies often included patients who had received multiple lines of cytoreductive therapy, including alkylating agents, which are known to increase the rate of leukemic transformation,^{22,23} thus rendering these findings difficult to interpret. Transformation to AML is diagnosed in the presence of ≥20% blast cells in the blood and/or bone marrow. Of note, patients with *JAK2* V617F-positive ET may develop AML that is negative for the *JAK2* mutation.²⁴⁻²⁶

Controversies in the diagnosis of ET

Distinguishing ET from PMF

ET is heterogeneous with regards to diagnostic, clinical, and laboratory features, and there has been considerable debate over the existence of distinct subgroups. Some of this heterogeneity, such as variation in diagnostic blood counts and bone marrow cellularity, reflects the presence or absence of mutations in *JAK2* or *MPL*,^{4,7,14,27} and constitutional genetic differences are also likely to contribute. The current WHO classification proposes that bone marrow histology can be used as a tool to subdivide ET into so-called “true ET” and “prefibrotic myelofibrosis”¹³ and suggests that true ET is a benign and stable condition whereas prefibrotic myelofibrosis progresses to clinically overt myelofibrosis.²⁸ However many of the histologic criteria used to define prefibrotic myelofibrosis, such as megakaryocyte morphology, are subjective and difficult to apply reproducibly, even by experienced hematopathologists.¹⁴ We therefore avoid the terms true ET and prefibrotic myelofibrosis in our practice.

A second area of debate relates to patients with an isolated thrombocytosis who show an increase in bone marrow reticulin fibrosis at diagnosis but lack any other features of PMF (Figure 2). Such patients clearly have an MPN but cannot be classified as having either ET or PMF according to WHO criteria.¹³ Importantly, such cases are not unusual, with data from the PT-1 trial indicating that 15%-20% of ET patients harbor grade 3 or occasionally

grade 4 reticulin fibrosis at diagnosis (on a 0-4 scale, with grade 4 indicating the presence of collagen fibrosis), in the absence of other features of PMF.²⁹ Increased bone marrow fibrosis at diagnosis is associated with greater rates of myelofibrotic transformation, thrombosis, and hemorrhage but no change in overall survival.²⁹ The lack of a survival difference, together with the small number of complications even at greater reticulin levels, supports the concept that patients presenting with an isolated thrombocytosis but elevated reticulin have a relatively benign prognosis. We therefore follow BCSH guidelines according to which such patients are diagnosed and treated as ET.

A third area of controversy relates to the traditional view of ET and PMF as separate entities. More recently it has been suggested that PMF represents presentation in accelerated phase of a previously undiagnosed MPN, usually ET.^{1,14,30} This concept is supported by several lines of evidence: (1) PMF is clinically indistinguishable from myelofibrotic transformation of ET; (2) the prevalence of *JAK2* and *MPL* mutations are similar in ET and PMF; (3) laboratory (eg, cytogenetic changes) and clinical features (eg, increased rate of leukemic transformation) suggest PMF represents accelerated phase disease; and (4) patients with PMF may have thrombocytosis for many years before they are diagnosed (Figure 3). Of interest, the patient illustrated in Figure 3 had a platelet count of $450\text{--}500 \times 10^9/\text{L}$ at diagnosis of PMF but was subsequently found to have had counts lose to $1000 \times 10^9/\text{L}$ during the preceding 10 years. This finding indicates that ET patients presenting with marginally elevated platelet counts may represent either early-phase disease (platelet count on the way up) or late-phase disease (platelet count on the way down).

These various controversies over the boundary between ET and PMF are likely to be resolved in time as we gain greater molecular insights into these disorders. However, the current lack of a universally agreed classification will impair comparisons between clinical studies. In our view the WHO criteria place too much reliance on subjective histologic criteria, the variable application of which by different centers will result in a lack of comparability between patient cohorts. By contrast, the broader definition of ET adopted by BCSH guidelines has the advantage that it is easier to apply in a reproducible manner.

Distinguishing ET from PV

The distinction between ET and PV is, in theory, simple—patients with PV have an overt erythrocytosis that is lacking in ET. Unfortunately, in practice matters are more complex. Mounting evidence demonstrates that patients with *JAK2* V617F-positive ET represent a *forme fruste* of PV and exhibit PV-like features.^{7,30} ET and PV therefore form a phenotypic spectrum and there has been considerable debate over where to draw the line between them. Indeed, there are inherent problems in the use of continuous variables, such as hemoglobin, hematocrit, or red cell mass, to make this binary distinction, because the group of patients with borderline values will inevitably include both disorders, as illustrated in Figure 4A.

We take a pragmatic approach and base a diagnosis of PV on the presence of a *JAK2* mutation and a raised hematocrit (with or without supporting features such a low serum erythropoietin), an approach consistent with both WHO and BCSH guidelines.^{13,31} We recognize that, unless markedly elevated, hematocrit does not accurately predict an increased red cell mass,³² that serum erythropoietin levels do not distinguish PV from ET,⁷ and that ET patients, predominantly those with *JAK2* V617F-positive disease, may harbor an increased red cell mass despite a normal hematocrit.^{33,34} However, in the presence of a normal hematocrit and normal iron stores, the clinical significance of a raised red cell mass is unclear, and so we do not measure red cell mass in our ET patients.

Further progress in distinguishing ET from PV is likely to require a better understanding of their molecular pathogenesis. It has recently been reported that the distinct phenotypes of

*JAK2*V617F-positive ET and PV reflect differential STAT1 activation,³⁵ an observation that could lead to clinically useful biomarkers.

How we treat ET

Modification of cardiovascular risk factors

In our practice, all patients are screened for the presence of established cardiovascular risk factors, including hypertension, diabetes, smoking, hypercholesterolemia, and obesity, and treated where indicated according to local guidelines. The broad efficacy of the cholesterol-lowering statin drugs in the prevention of atherosclerotic disease has raised the possibility that such agents may be useful in ET, although this has yet to be tested in a prospective study.

Antiplatelet therapy

A large randomized trial in PV demonstrated a reduction in thrombotic events in those taking aspirin, without a concomitant increase in the risk of hemorrhage.³⁶ Retrospective studies have suggested a similar protective effect in ET,^{37,38} although the authors of one recent study suggested that low-risk patients may not derive benefit from antiplatelet therapy.³⁹ On the basis of current evidence, we recommend aspirin for all ET patients unless contraindicated. Although there are few data concerning the use of newer antiplatelet agents such as clopidogrel, their proven track record in atherosclerotic disease suggests they are appropriate for ET patients unable to tolerate aspirin.

Indications for cytoreductive therapy

The best established risk factors for thrombotic complications in ET are age older than 60 years or a history of previous thrombosis,^{16,40,41} and patients with these risk factors probably benefit from cytoreductive therapy.⁴² Risk factors for atherosclerotic disease also predict for thrombosis in ET patients,^{41,43,44} although it is unclear whether their presence necessitates cytoreductive therapy in the absence of high-risk ET (age > 60 years or history of thrombosis). The degree of thrombocytosis is not a reliable indicator of thrombotic risk, although very high levels may predict for hemorrhagic complications.^{16,41,45-48} Meta-analysis has confirmed an increased risk of venous and arterial thrombosis in *JAK2*V617F-positive compared with V617F-negative ET.^{49,50} Studies have also suggested that the size of the *JAK2*-mutant clone may be of prognostic significance in MPN patients, although data for ET patients are limited.²⁷ Increased leukocyte count or increased bone marrow fibrosis at diagnosis are also independent predictors of thrombotic complications.^{15,29,48}

We stratify ET patients on the basis of thrombotic risk (Table 4) and recommend cytoreductive therapy for all high-risk patients. Cytoreduction is also considered in those with previous serious hemorrhage (eg, requiring hospitalization or red cell transfusion) that is thought to be related to ET. Microvascular complications, such as erythromelalgia, generally settle with antiplatelet therapy alone,³⁸ and cytoreductive therapy is only considered for refractory cases. Those with indicators of atherosclerotic disease in the absence of high-risk ET are assessed on a case-by-case basis, taking into account the severity of each cardiovascular risk. For example in the absence of high-risk features, cytoreductive therapy would not generally be recommended for a patient with well-controlled hypertension but would be considered in someone with poorly controlled diabetes or a strong family history of early onset atherosclerotic disease. The role of the platelet count in directing cytoreductive therapy remains contentious. Many physicians still recommend cytoreductive therapy in patients with platelets > 1500 × 10⁹/L, although it may be reasonable to use a greater cut-off in younger patients. There are, as yet, no prospective clinical data on the utility of novel thrombotic risk factors, such as *JAK2* mutation status,

mutant allele burden, leukocyte count, and bone marrow fibrosis. We therefore do not currently use these factors to guide therapeutic decisions.

Patients without high-risk features can be divided into low risk (age < 40 years) and intermediate risk (age 40-60 years). Cytoreductive therapy is unlikely to offer a significant protective effect for those with low risk of disease, in whom the a priori risk of thrombosis is small. There is currently little evidence available to guide treatment decisions in the intermediate risk group. The ongoing PT-1 trials (<http://www.haem.cam.ac.uk/pages/pt1/>), which comprise a randomized trial of hydroxycarbamide and aspirin versus aspirin alone for intermediate-risk patients and an observational study of low-risk patients treated with aspirin alone, will provide prospective data to help clarify therapeutic decisions for these patients.

Choice of cytoreductive agent

Hydroxycarbamide (also known as hydroxyurea) is the only cytoreductive agent proven to reduce thrombotic events in a randomized controlled trial⁴² and remains our recommended first-line therapy for the majority of patients requiring treatment (Table 5). Concerns have been raised, however, about a possible increased risk of leukemic transformation with this agent. Clinical studies have given conflicting results,^{23,51-54} further confounded by inclusion of patients who have received multiple cytotoxic agents, lack of proper controls, retrospective data collection, and relatively short follow-up. Further evidence cited in support of a mutagenic role for hydroxycarbamide includes a possible association with deletions of 17p (harboring the *TP53* locus),^{51,55-57} increased risk of skin neoplasia during prolonged therapy,⁵⁸ and possible clastogenic activity in vitro.⁵⁹ By contrast, hydroxycarbamide appears nonleukemogenic in the treatment of sickle cell disease⁶⁰ and does not appear to increase in vivo mutation rates in sickle cell or MPN patients.⁶¹ At this time it is unclear whether single agent hydroxycarbamide is leukemogenic; however, any increased risk is likely to be small and should be balanced against the reduction in thrombotic complications because thrombosis remains the major source of morbidity in ET.

Anagrelide reduces the platelet count by inhibition of megakaryocyte differentiation,⁶² and we currently use it as second-line therapy for patients in whom hydroxycarbamide is inadequate or not tolerated. Combined therapy with anagrelide and hydroxycarbamide has also been used successfully in our clinic in circumstances in which hydroxycarbamide alone has failed to control the platelet count. Anagrelide does not affect the white cell count, but anemia is common and often progressive.²⁹ Up to one-third of patients cannot tolerate anagrelide because of side effects, many of which result from its vasodilatory and positive inotropic actions, including palpitations and arrhythmias, fluid retention, heart failure, and headaches.^{19,63} The use of this drug requires particular caution in elderly patients or those with pre-existing cardiac disease. Although anagrelide is not cytotoxic and therefore unlikely to be leukemogenic, the PT-1 trial demonstrated that anagrelide plus aspirin was inferior to hydroxycarbamide plus aspirin in high-risk ET patients. Despite equivalent control of the platelet count, anagrelide-treated patients experienced greater rates of arterial thrombosis, major hemorrhage, and progression to myelofibrosis and were more likely to be intolerant of their therapy.¹⁹ In contrast to hydroxycarbamide, anagrelide therapy was also associated with an increase in bone marrow reticulin over time.²⁹ Comparison of patients in the PT-1 (comparison of hydroxycarbamide vs anagrelide¹⁹) and Italian (comparison of hydroxycarbamide vs no cytoreductive therapy⁴²) prospective studies suggests that anagrelide provides partial protection from thrombosis.⁶⁴ The reduced efficacy of anagrelide compared with hydroxycarbamide in thrombosis prevention was limited to those with *JAK2* V617F-positive ET, probably reflecting increased sensitivity of these patients to the cytoreductive effects of hydroxycarbamide.⁷ However, the increased risk of myelofibrotic transformation associated with anagrelide was observed in V617F-positive and negative patients.

Preliminary reports of the final results of the ANAHYDRET (Anagrelide versus Hydroxyurea in ET) trial claim to show that anagrelide is not inferior to hydroxycarbamide in the treatment of ET.⁶⁵ However, compared with PT-1, the number of patients enrolled was small, the duration of follow-up relatively short (539 patient-years compared with 2653 patient-years in PT-1), and considerably fewer end-point events were recorded.³⁰ It therefore seems highly unlikely that the ANAHYDRET study had the statistical power necessary to detect the differences observed in the PT-1 study. In addition, the “noninferiority” design of the ANAHYDRET study seems inappropriate, especially after the marked inferiority documented by the PT-1 trial. Such designs define noninferiority up to a predetermined limit of “tolerable inferiority,” but often this limit is entirely arbitrary or selected with an eye on obtaining regulatory approval, and risks failing to detect clinically relevant differences between the treatment arms. Indeed, the whole ethical basis for conducting noninferiority trials has recently been called into question.⁶⁶

Recombinant interferon α is free from leukemogenic or teratogenic effects, is effective at controlling the platelet count in ET, and may reduce *JAK2* mutant allele burden.^{67,68} It should be noted, however, that interferon has not been shown to protect from thrombotic complications, and the PT-1 trial reminds us that 2 agents that result in equivalent control of the platelet count may nonetheless be associated with very different thrombotic risk.¹⁹ Interferon therapy is still considered by many as experimental, and its use in the MPN is not licensed in Europe or North America. Therapy is often associated with significant side-effects, and although pegylated interferon may be more convenient, toxicity appears similar to the native compound.^{67,69} Interferon is used in our clinic for young patients (typically those < 40 years), for those wishing to start a family, or for those in whom hydroxycarbamide may be inappropriate. We try and avoid the use of interferon in older patients, who are generally less able to tolerate this agent.

Radioactive phosphorus and alkylating agents such as busulphan are effective at controlling the platelet count but are associated with an increased risk of progression to acute leukemia, particularly when used sequentially with hydroxycarbamide.^{23,52} Both agents can be given intermittently with long intervals between doses and may be useful in treating older patients who are unable to attend the clinic on a regular basis. Pipobroman, a piperazine derivative, is effective at reducing the platelet count in ET, although there is little direct evidence for thrombosis prevention.⁷⁰ Pipobroman is chemically similar to the alkylating agents and is associated with an increased risk of leukemic transformation when used in the long-term treatment of PV.⁷¹ In our clinic, the use of pipobroman and other alkylating agents is restricted to older patients (typically those > 75 years), where they are used as second- or third-line agents for those who are unable to tolerate hydroxycarbamide, for example, because of nonhealing leg ulcers.

Response to therapy

The traditional goal of cytoreductive therapy in ET has been resolution of symptoms and normalization of the platelet count. However, retrospective studies have identified an association between leukocytosis and thrombosis,⁴⁸ raising the possibility that controlling the white cell count may be important. Recent prospective data from the PT-1 trial have shed further light on this issue, with analysis of blood counts revealing that a leukocyte (but not platelet) count above the normal range during follow-up predicted for thrombosis in the subsequent 60 days (P.J.C., C. MacLean, P.A.B., G. Buck, K. Wheatley, C. N. Harrison, A.R.G., manuscript in preparation). We now use freedom from ET-related symptoms together with normal platelet and leukocyte counts as our primary therapeutic endpoints, although it should be noted that this approach has yet to be validated in a prospective clinical study.

Special considerations: pregnancy

First-trimester fetal loss complicates 25%-50% of pregnancies in ET patients, with other complications such as intrauterine growth retardation, stillbirth, and preeclampsia also occurring more frequently.⁷²⁻⁷⁷ Such complications occur irrespective of the platelet count before conception but appear to be more common in those with *JAK2* V617F-positive disease.^{74,77} Whether the use of aspirin or cytoreductive agents can improve pregnancy outcome is uncertain; researchers have reported contradictory results.⁷²⁻⁷⁷ Moreover, the use of aspirin during pregnancy does not benefit non-ET patients with a history of recurrent miscarriage.⁷⁸ However, a large meta-analysis of non-ET preeclampsia patients suggested that aspirin use in pregnancy is safe for mother and fetus,⁷⁹ and we therefore recommend aspirin for all pregnant ET patients (unless otherwise contraindicated).

We consider the use of cytoreductive therapy for all pregnant women with a history of thrombosis. We also consider cytoreductive therapy for those with previous obstetric complications, such as stillbirth or recurrent miscarriage. Because the platelet count often decreases during pregnancy, we do not consider a platelet count of greater than $1500 \times 10^9/L$ as an absolute indication for cytoreductive therapy, and such patients are considered on a case-by-case basis.

Although hydroxycarbamide has been used during pregnancy, usually without adverse effects for mother or fetus, it is teratogenic in nonhuman mammals⁸⁰ and should therefore be avoided. Anagrelide can cross the placenta with unknown effects on fetal development and should also be avoided. Interferon α is nonteratogenic and is the agent of choice should cytoreductive therapy be required. Although studies in ET are lacking, thromboprophylaxis appears safe in pregnancy⁸¹ and may be considered for patients with a history of thrombosis or recurrent pregnancy loss; in those with a previous occurrence of thrombosis, treatment should be continued for at least 6 weeks postpartum. Overall, pregnancy does not appear to affect the natural history of ET.⁷² Pregnant ET patients should ideally be managed in a center at which regular fetal monitoring can be performed, with good communication between the obstetric, hematology, and anesthetic departments. In animal studies, hydroxycarbamide is associated with reduced spermatogenesis and genetic damage to spermatogonia.⁸⁰ We therefore advise male patients requiring cytoreductive treatment to switch to interferon α before attempted conception.

Special considerations: surgery

Although perioperative thrombotic and bleeding complications appear increased in ET patients, it is not clear whether this can be ameliorated by therapeutic intervention.⁸² In general, we stop antiplatelet agents 7-10 days before major surgery or surgery to critical sites and reintroduce as soon as the surgeon is confident of hemostasis. Postoperative thromboprophylaxis is recommended according to usual guidelines for the specific procedure. For patients receiving cytoreductive therapy who are undergoing elective surgery, the blood count is optimized preoperatively, and interruptions in therapy are kept to a minimum. For patients not receiving cytoreductive treatment, temporary therapy is considered on a case-by-case basis, after assessment of the patient's thrombotic risk profile, degree of thrombocytosis (because greater platelet counts may predict for hemorrhage⁴⁷), and the nature of the surgery. Splenectomy in ET patients generally results in a sharp increase in platelet count that may lead to thrombotic and hemorrhagic complications. Unless otherwise contraindicated, we commence cytoreductive therapy before splenectomy in ET patients with an increased or high-normal platelet count, aiming for a platelet count in the mid-normal range before surgery. Postoperative thromboprophylaxis and daily monitoring of blood counts are also recommended.

How we treat advanced-phase disease

The problems and complications associated with myelofibrotic transformation of ET are similar to de novo PMF, and we manage the conditions in the same way. Therapy of post-ET AML is often limited by the age and comorbidities and supportive treatment is often the most appropriate strategy. Overall the prognosis of AML secondary to an MPN is very poor. Younger patients who achieve remission with AML induction therapy are considered for allogeneic bone marrow transplantation.

Controversies in the management of ET

The choice of cytoreductive therapy in the younger patient

Hydroxycarbamide has proven efficacy in the prevention of thrombosis, the major source of morbidity in this condition, but concerns remain about potential leukemogenicity.⁵⁷ Because the incidence of leukemic transformation in ET increases with disease duration,^{15,16} this concern is particularly relevant to younger patients who may require therapy for several decades. Interferon α is not leukemogenic, but efficacy data are lacking, and some patients experience intolerable side-effects. Anagrelide is not cytotoxic and likely not mutagenic. However, the PT-1 trial demonstrated inferiority of anagrelide to hydroxycarbamide in the prevention of thrombosis and identified an increased risk of myelofibrotic transformation with anagrelide therapy.¹⁹

It is our current practice to recommend a trial of interferon α to patients younger than the age of 40 years who require therapy. Approaches to maximizing tolerance include slow escalation from a low starting dose (eg, 1MU 3 times a week initially), administration at bedtime with prophylactic acetaminophen (paracetamol), dose reduction once control is achieved (to the lowest dose that affords blood count control), and support from specialist nursing staff between visits to the clinic. If interferon α is not tolerated, the pros and cons of hydroxycarbamide versus anagrelide are discussed in detail with each patient. For those receiving anagrelide, we recommend baseline bone marrow studies to assess reticulin fibrosis with follow-up bone marrow histology every 2-3 years while therapy continues. Cessation of anagrelide should be considered in those with increasing reticulin fibrosis because anagrelide-associated fibrosis is reversible in some cases.²⁹

Indications for cytoreductive therapy in ET versus PV

As outlined previously in this article, ET and PV form a phenotypic continuum with significant overlap in hemoglobin and platelet levels. These observations call into question the rationale for different therapeutic strategies in these 2 disorders, particularly the use of a target hematocrit level to guide treatment in PV but not ET. The primary aim of therapeutic intervention in both ET and PV is the prevention of thrombosis. Whereas thrombotic risk appears greater in V617F-positive compared with V617F-negative ET,^{49,50} retrospective data suggest comparable thrombosis rates in V617F-positive ET and PV.⁸³ Common predictors of thrombosis in ET and PV include older age, thrombotic history, and increased white cell count,^{16,40,41,84,85} with hematocrit identified by some but not all studies as an important predictor of thrombosis in PV.^{86,87} Given the similarities between V617F-positive ET and PV, the time may be approaching when these disorders are stratified and managed as a single disease entity, with older age, history of previous thrombosis, or an increased hematocrit indicating high-risk disease and mandating cytoreductive therapy. Given the lower thrombosis rates in V617F-negative ET, it may be that indications for therapy could safely be relaxed in this group. Clearly further prospective trials are necessary before these goals can be realized, with studies enrolling both ET and PV patients allowing for prospective comparison of complication rates and assessment of novel risk factors such as mutation status, leukocyte count and bone marrow fibrosis.

Future directions

In the past 5 years we have witnessed dramatic advances in our understanding of the pathogenesis, classification, and therapy of ET. The identification of additional molecular markers is likely to be needed to clarify the overlap between ET, PV, and PMF. Novel risk factors such as leukocyte count, *JAK2* mutation status, and bone marrow fibrosis may provide more precise therapeutic stratification, an approach that awaits validation in prospective studies. With regards to therapy, direct comparison of interferon α and hydroxycarbamide seems timely. *JAK2* inhibitors may prove useful for accelerated-phase disease⁸⁸ but given the excellent prognosis of chronic phase ET, it is unclear whether there is likely to be a role for *JAK2* inhibitors in the majority of ET patients.

Acknowledgments

We thank Dr Penny Wright for helpful comments on bone marrow histology and our colleagues in the NCRI MPN study group for many helpful discussions.

Work in the authors' laboratories is supported by Leukemia and Lymphoma Research UK, Cancer Research UK, the Kay Kendall Leukemia Fund, the National Institute for Health Research Cambridge Biomedical Research Center, and the Leukemia & Lymphoma Society of America. P.J.C. is supported by a Wellcome Trust Senior Clinical Research Fellowship and P.A.B. by a Kay Kendall Leukemia Fund Intermediate Fellowship.

References

1. Campbell PJ, Green AR. The myeloproliferative disorders. *N Engl J Med*. 2006; 355(23):2452–2466. [PubMed: 17151367]
2. Levine RL, Pardanani A, Tefferi A, Gilliland DG. Role of *JAK2* in the pathogenesis and therapy of myeloproliferative disorders. *Nat Rev Cancer*. 2007; 7(9):673–683. [PubMed: 17721432]
3. Pikman Y, Lee BH, Mercher T, et al. MPLW515L is a novel somatic activating mutation in myelofibrosis with myeloid metaplasia. *PLoS Med*. 2006; 3(7):e270. [PubMed: 16834459]
4. Beer PA, Campbell PJ, Scott LM, et al. MPL mutations in myeloproliferative disorders: analysis of the PT-1 cohort. *Blood*. 2008; 112(1):141–149. [PubMed: 18451306]
5. Vannucchi AM, Antonioli E, Guglielmelli P, et al. Characteristics and clinical correlates of MPL 515W>L/K mutation in essential thrombocythemia. *Blood*. 2008; 112(3):844–847. [PubMed: 18519816]
6. Delhommeau F, Dupont S, Valle V Della, et al. Mutation in *TET2* in myeloid cancers. *N Engl J Med*. 2009; 360(22):2289–2301. [PubMed: 19474426]
7. Campbell PJ, Scott LM, Buck G, et al. Definition of subtypes of essential thrombocythaemia and relation to polycythaemia vera based on *JAK2* V617F mutation status: a prospective study. *Lancet*. 2005; 366(9501):1945–1953. [PubMed: 16325696]
8. Pich A, Riera L, Sismondi F, et al. *JAK2*V617F activating mutation is associated with the myeloproliferative type of chronic myelomonocytic leukaemia. *J Clin Pathol*. 2009; 62(9):798–801. [PubMed: 19734476]
9. Buss DH, Cashell AW, O'Connor ML, Richards F II, Case LD. Occurrence, etiology, and clinical significance of extreme thrombocytosis: a study of 280 cases. *Am J Med*. 1994; 96(3):247–253. [PubMed: 8154513]
10. Griesshammer M, Bangerter M, Sauer T, Wennauer R, Bergmann L, Heimpel H. Aetiology and clinical significance of thrombocytosis: analysis 732 patients with an elevated platelet count. *J Intern Med*. 1999; 245(3):295–300. [PubMed: 10205592]
11. Bench AJ, Nacheva EP, Champion KM, Green AR. Molecular genetics and cytogenetics of myeloproliferative disorders. *Baillieres Clin Haematol*. 1998; 11(4):819–848. [PubMed: 10640219]
12. Harrison CN, Bareford D, Butt N, et al. BCSH guidelines for investigation and management of patients presenting with a thrombocytosis. *Br J Haematol*. 2010; 149(3):352–375. [PubMed: 20331456]

13. Swerdlow, SH.; Campo, E.; Harris, NL., et al. WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues. IARC Press; Lyon: 2008.
14. Wilkins BS, Erber WN, Bareford D, et al. Bone marrow pathology in essential thrombocythemia: interobserver reliability and utility for identifying disease subtypes. *Blood*. 2008; 111(1):60–70. [PubMed: 17885079]
15. Wolanskyj AP, Schwager SM, McClure RF, Larson DR, Tefferi A. Essential thrombocythemia beyond the first decade: life expectancy, long-term complication rates, and prognostic factors. *Mayo Clin Proc*. 2006; 81(2):159–166. [PubMed: 16471068]
16. Passamonti F, Rumi E, Arcaini L, et al. Prognostic factors for thrombosis, myelofibrosis, and leukemia in essential thrombocythemia: a study of 605 patients. *Haematologica*. 2008; 93:1645–1651. [PubMed: 18790799]
17. Cervantes F, Alvarez-Larran A, Talam C, Gomez M, Montserrat E. Myelofibrosis with myeloid metaplasia following essential thrombocythemia: actuarial probability, presenting characteristics and evolution in a series of 195 patients. *Br J Haematol*. 2002; 118(3):786–790. [PubMed: 12181046]
18. Barosi G, Ambrosetti A, Finelli C, et al. The Italian Consensus Conference on Diagnostic Criteria for Myelofibrosis with Myeloid Metaplasia. *Br J Haematol*. 1999; 104(4):730–737. [PubMed: 10192432]
19. Harrison CN, Campbell PJ, Buck G, et al. Hydroxyurea compared with anagrelide in high-risk essential thrombocythemia. *N Engl J Med*. 2005; 353(1):33–45. [PubMed: 16000354]
20. Beer PA, Campbell PJ, Green AR. Comparison of different criteria for the diagnosis of primary myelofibrosis reveals limited clinical utility for measurement of serum lactate dehydrogenase. *Haematologica*. 2010; 95:1960–1963. [PubMed: 20534696]
21. Kiladjian JJ, Rain JD, Bernard JF, Briere J, Chomienne C, Fenaux P. Long-term incidence of hematological evolution in three French prospective studies of hydroxyurea and pipobroman in polycythemia vera and essential thrombocythemia. *Semin Thromb Hemost*. 2006; 32(4 Pt 2):417–421. [PubMed: 16810617]
22. Berk PD, Goldberg JD, Silverstein MN, et al. Increased incidence of acute leukemia in polycythemia vera associated with chlorambucil therapy. *N Engl J Med*. 1981; 304(8):441–447. [PubMed: 7005681]
23. Finazzi G, Caruso V, Marchioli R, et al. Acute leukemia in polycythemia vera: an analysis of 1638 patients enrolled in a prospective observational study. *Blood*. 2005; 105(7):2664–2670. [PubMed: 15585653]
24. Campbell PJ, Baxter EJ, Beer PA, et al. Mutation of JAK2 in the myeloproliferative disorders: timing, clonality studies, cytogenetic associations, and role in leukemic transformation. *Blood*. 2006; 108(10):3548–3555. [PubMed: 16873677]
25. Theocharides A, Boissinot M, Girodon F, et al. Leukemic blasts in transformed JAK2-V617F-positive myeloproliferative disorders are frequently negative for the JAK2-V617F mutation. *Blood*. 2007; 110(1):375–379. [PubMed: 17363731]
26. Beer PA, Delhommeau F, Lecouedic JP, et al. Two routes to leukemic transformation following a JAK2 mutation-positive myeloproliferative neoplasm. *Blood*. 2010; 115(14):2891–2900. [PubMed: 20008300]
27. Vannucchi AM, Antonioli E, Guglielmelli P, Pardanani A, Tefferi A. Clinical correlates of JAK2V617F presence or allele burden in myeloproliferative neoplasms: a critical reappraisal. *Leukemia*. 2008; 22(7):1299–1307. [PubMed: 18496562]
28. Thiele J, Kvasnicka HM. Chronic myeloproliferative disorders with thrombocythemia: a comparative study of two classification systems (PVSG, WHO) on 839 patients. *Ann Hematol*. 2003; 82(3):148–152. [PubMed: 12634946]
29. Campbell PJ, Bareford D, Erber WN, et al. Reticulin accumulation in essential thrombocythemia: prognostic significance and relationship to therapy. *J Clin Oncol*. 2009; 27(18):2991–2999. [PubMed: 19364963]
30. Beer PA, Green AR. Pathogenesis and management of essential thrombocythemia. *Hematology Am Soc Hematol Educ Program*. 2009:621–628. [PubMed: 20008247]

31. McMullin MF, Reilly JT, Campbell P, et al. Amendment to the guideline for diagnosis and investigation of polycythaemia/erythrocytosis. *Br J Haematol*. 2007; 138(6):821–822. [PubMed: 17672880]
32. Spivak JL, Silver RT. The revised World Health Organization diagnostic criteria for polycythemia vera, essential thrombocytosis, and primary myelofibrosis: an alternative proposal. *Blood*. 2008; 112(2):231–239. [PubMed: 18401028]
33. Cassinat B, Laguillier C, Gardin C, et al. Classification of myeloproliferative disorders in the JAK2 era: is there a role for red cell mass? *Leukemia*. 2008; 22(2):452–453. [PubMed: 17713549]
34. Sirhan S, Fairbanks VF, Tefferi A. Red cell mass and plasma volume measurements in polycythemia: evaluation of performance and practical utility. *Cancer*. 2005; 104(1):213–215. [PubMed: 15889449]
35. Chen E, Beer PA, Godfrey AL, et al. Distinct clinical phenotypes associated with JAK2V617F reflect differential STAT1 signaling. *Cancer Cell*. 2010; 18(5):524–535. [PubMed: 21074499]
36. Landolfi R, Marchioli R, Kutti J, et al. Efficacy and safety of low-dose aspirin in polycythemia vera. *N Engl J Med*. 2004; 350(2):114–124. [PubMed: 14711910]
37. Jensen MK, de Nully Brown P, Nielsen OJ, Hasselbalch HC. Incidence, clinical features and outcome of essential thrombocythaemia in a well defined geographical area. *Eur J Haematol*. 2000; 65(2):132–139. [PubMed: 10966175]
38. Michiels JJ, van Genderen PJ, Lindemans J, van Vliet HH. Erythromelalgic, thrombotic and hemorrhagic manifestations in 50 cases of thrombocythemia. *Leuk Lymphoma*. 1996; 22(suppl 1):47–56. [PubMed: 8951772]
39. Alvarez-Larran A, Cervantes F, Pereira A, et al. Observation versus antiplatelet therapy as primary prophylaxis for thrombosis in low-risk essential thrombocythemia. *Blood*. 2010; 116(8):1205–1210. quiz 1387. [PubMed: 20508163]
40. Cortelazzo S, Viero P, Finazzi G, D'Emilio A, Rodeghiero F, Barbui T. Incidence and risk factors for thrombotic complications in a historical cohort of 100 patients with essential thrombocythemia. *J Clin Oncol*. 1990; 8(3):556–562. [PubMed: 2307991]
41. Besses C, Cervantes F, Pereira A, et al. Major vascular complications in essential thrombocythemia: a study of the predictive factors in a series of 148 patients. *Leukemia*. 1999; 13(2):150–154. [PubMed: 10025886]
42. Cortelazzo S, Finazzi G, Ruggeri M, et al. Hydroxyurea for patients with essential thrombocythemia and a high risk of thrombosis. *N Engl J Med*. 1995; 332(17):1132–1136. [PubMed: 7700286]
43. Alvarez-Larran A, Cervantes F, Bellosillo B, et al. Essential thrombocythemia in young individuals: frequency and risk factors for vascular events and evolution to myelofibrosis in 126 patients. *Leukemia*. 2007; 21(6):1218–1223. [PubMed: 17519959]
44. Radaelli F, Colombi M, Calori R, et al. Analysis of risk factors predicting thrombotic and/or haemorrhagic complications in 306 patients with essential thrombocythemia. *Hematol Oncol*. 2007; 25(3):115–120. [PubMed: 17464935]
45. Carobbio A, Antonioli E, Guglielmelli P, et al. Leukocytosis and risk stratification assessment in essential thrombocythemia. *J Clin Oncol*. 2008; 26(16):2732–2736. [PubMed: 18443353]
46. Tefferi A, Fonseca R, Pereira DL, Hoagland HC. A long-term retrospective study of young women with essential thrombocythemia. *Mayo Clin Proc*. 2001; 76(1):22–28. [PubMed: 11155408]
47. Fenaux P, Simon M, Caulier MT, Lai JL, Goudemand J, Bauters F. Clinical course of essential thrombocythemia in 147 cases. *Cancer*. 1990; 66(3):549–556. [PubMed: 2364366]
48. Carobbio A, Finazzi G, Antonioli E, et al. Thrombocytosis and leukocytosis interaction in vascular complications of essential thrombocythemia. *Blood*. 2008; 112(8):3135–3137. [PubMed: 18587010]
49. Dahabreh IJ, Zoi K, Giannouli S, Zoi C, Loukopoulos D, Voulgarelis M. Is JAK2 V617F mutation more than a diagnostic index? A meta-analysis of clinical outcomes in essential thrombocythemia. *Leuk Res*. 2009; 33(1):67–73. [PubMed: 18632151]
50. Lussana F, Caberlon S, Pagani C, Kamphuisen PW, Buller HR, Cattaneo M. Association of V617F Jak2 mutation with the risk of thrombosis among patients with essential thrombocythaemia or

- idiopathic myelofibrosis: a systematic review. *Thromb Res.* 2009; 124(4):409–417. [PubMed: 19299003]
51. Sterkers Y, Preudhomme C, Lai JL, et al. Acute myeloid leukemia and myelodysplastic syndromes following essential thrombocythemia treated with hydroxyurea: high proportion of cases with 17p deletion. *Blood.* 1998; 91(2):616–622. [PubMed: 9427717]
 52. Nielsen I, Hasselbalch HC. Acute leukemia and myelodysplasia in patients with a Philadelphia chromosome negative chronic myeloproliferative disorder treated with hydroxyurea alone or with hydroxyurea after busulphan. *Am J Hematol.* 2003; 74(1):26–31. [PubMed: 12949887]
 53. Gangat N, Wolanskyj AP, McClure RF, et al. Risk stratification for survival and leukemic transformation in essential thrombocythemia: a single institutional study of 605 patients. *Leukemia.* 2007; 21(2):270–276. [PubMed: 17170720]
 54. Björkholm J, Derolf AR, Ekstrand C, et al. Risk For AML/MDS transformation in Philadelphia negative chronic myeloproliferative neoplasms— a population-based nested case-control study in Sweden. *Haematologica.* 2009; 94(suppl 2):438.
 55. Merlat A, Lai JL, Sterkers Y, et al. Therapy-related myelodysplastic syndrome and acute myeloid leukemia with 17p deletion. A report on 25 cases. *Leukemia.* 1999; 13(2):250–257. [PubMed: 10025899]
 56. Thoennissen NH, Krug UO, Lee DH, et al. Prevalence and prognostic impact of allelic imbalances associated with leukemic transformation of Philadelphia chromosome-negative myeloproliferative neoplasms. *Blood.* 2010; 115(14):2882–2890. [PubMed: 20068225]
 57. Spivak JL. An inconvenient truth. *Blood.* 2010; 115(14):2727–2728. [PubMed: 20378759]
 58. Vassallo C, Passamonti F, Merante S, et al. Muco-cutaneous changes during long-term therapy with hydroxyurea in chronic myeloid leukaemia. *Clin Exp Dermatol.* 2001; 26(2):141–148. [PubMed: 11298103]
 59. Liu L, Zhu S, Gong Z, Low BC. K-ras/PI3K-Akt signaling is essential for zebrafish hematopoiesis and angiogenesis. *PLoS ONE.* 2008; 3(8):e2850. [PubMed: 18682746]
 60. Lanzkron S, Strouse JJ, Wilson R, et al. Systematic review: hydroxyurea for the treatment of adults with sickle cell disease. *Ann Intern Med.* 2008; 148(12):939–955. [PubMed: 18458272]
 61. Hanft VN, Fruchtman SR, Pickens CV, Rosse WF, Howard TA, Ware RE. Acquired DNA mutations associated with in vivo hydroxyurea exposure. *Blood.* 2000; 95(11):3589–3593. [PubMed: 10828048]
 62. Solberg LA Jr, Tefferi A, Oles KJ, et al. The effects of anagrelide on human megakaryocytopoiesis. *Br J Haematol.* 1997; 99(1):174–180. [PubMed: 9359521]
 63. Storen EC, Tefferi A. Long-term use of anagrelide in young patients with essential thrombocythemia. *Blood.* 2001; 97(4):863–866. [PubMed: 11159509]
 64. Campbell PJ, Green AR. Management of polycythemia vera and essential thrombocythemia. *Hematology.* 2005; 2005(1):201–208. [PubMed: 16304381]
 65. Gisslinger H, Gotic M, Holowiecki J, et al. Final results of the ANAHYDRET-study: non-inferiority of anagrelide compared to hydroxyurea in newly diagnosed WHO-essential thrombocythemia patients [abstracts]. *Blood.* 2008; 112(11):661. [PubMed: 18505782]
 66. Garattini S, Bertele V. Non-inferiority trials are unethical because they disregard patients' interests. *Lancet.* 2007; 370(9602):1875–1877. [PubMed: 17959239]
 67. Kiladjian JJ, Chomienne C, Fenaux P. Interferon-alpha therapy in bcr-abl-negative myeloproliferative neoplasms. *Leukemia.* 2008; 22(11):1990–1998. [PubMed: 18843285]
 68. Quintas-Cardama A, Kantarjian H, Manshour T, et al. Pegylated interferon alfa-2a yields high rates of hematologic and molecular response in patients with advanced essential thrombocythemia and polycythemia vera. *J Clin Oncol.* 2009; 27(32):5418–5424. [PubMed: 19826111]
 69. Michallet M, Maloisel F, Delain M, et al. Pegylated recombinant interferon alpha-2b vs recombinant interferon alpha-2b for the initial treatment of chronic-phase chronic myelogenous leukemia: a phase III study. *Leukemia.* 2004; 18(2):309–315. [PubMed: 14671645]
 70. Passamonti F, Rumi E, Malabarba L, et al. Long-term follow-up of young patients with essential thrombocythemia treated with pipobroman. *Ann Hematol.* 2004; 83(8):495–497. [PubMed: 15175894]

71. Kiladjian J-J, Chevret S, Dosquet C, Fenaux P, Chomienne C, Rain J-D. Long-term outcome in polycythemia vera (PV): final analysis of a randomized trial comparing hydroxyurea (HU) to pipobroman (Pi) [abstract]. *Blood*. 2008; 112(11):1746.
72. Beressi AH, Tefferi A, Silverstein MN, Pettitt RM, Hoagland HC. Outcome analysis of 34 pregnancies in women with essential thrombocythemia. *Arch Intern Med*. 1995; 155(11):1217–1222. [PubMed: 7763128]
73. Wright CA, Tefferi A. A single institutional experience with 43 pregnancies in essential thrombocythemia. *Eur J Haematol*. 2001; 66(3):152–159. [PubMed: 11350483]
74. Passamonti F, Randi ML, Rumi E, et al. Increased risk of pregnancy complications in patients with essential thrombocythemia carrying the JAK2 (617V>F) mutation. *Blood*. 2007; 110(2):485–489. [PubMed: 17426257]
75. Griesshammer M, Bergmann L, Pearson T. Fertility, pregnancy and the management of myeloproliferative disorders. *Baillieres Clin Haematol*. 1998; 11(4):859–874. [PubMed: 10640221]
76. Niittyvuopio R, Juvonen E, Kaaja R, et al. Pregnancy in essential thrombocythaemia: experience with 40 pregnancies. *Eur J Haematol*. 2004; 73(6):431–436. [PubMed: 15522066]
77. Melillo L, Tieghi A, Candoni A, et al. Outcome of 122 pregnancies in essential thrombocythemia patients: a report from the Italian registry. *Am J Hematol*. 2009; 84(10):636–640. [PubMed: 19705431]
78. Kaandorp SP, Goddijn M, van der Post JA, et al. Aspirin plus heparin or aspirin alone in women with recurrent miscarriage. *N Engl J Med*. 2010; 362(17):1586–1596. [PubMed: 20335572]
79. Askie LM, Duley L, Henderson-Smart DJ, Stewart LA. Antiplatelet agents for prevention of preeclampsia: a meta-analysis of individual patient data. *Lancet*. 2007; 369(9575):1791–1798. [PubMed: 17512048]
80. Liebelt EL, Balk SJ, Faber W, et al. NTPCERHR expert panel report on the reproductive and developmental toxicity of hydroxyurea. *Birth Defects Res B Dev Reprod Toxicol*. 2007; 80(4):259–366. [PubMed: 17712860]
81. Patel JP, Hunt BJ. Where do we go now with low molecular weight heparin use in obstetric care? *J Thromb Haemost*. 2008; 6(9):1461–1467. [PubMed: 18532999]
82. Ruggeri M, Rodeghiero F, Tositto A, et al. Post-surgery outcomes in patients with polycythemia vera and essential thrombocythemia: a retrospective survey. *Blood*. 2008; 111(2):666–671. [PubMed: 17909074]
83. Carobbio A, Finazzi G, Antonioli E, et al. JAK2V617F allele burden and thrombosis: a direct comparison in essential thrombocythemia and polycythemia vera. *Exp Hematol*. 2009; 37(9):1016–1021. [PubMed: 19559071]
84. Marchioli R, Finazzi G, Landolfi R, et al. Vascular and neoplastic risk in a large cohort of patients with polycythemia vera. *J Clin Oncol*. 2005; 23(10):2224–2232. [PubMed: 15710945]
85. Barbui T, Carobbio A, Rambaldi A, Finazzi G. Perspectives on thrombosis in essential thrombocythemia and polycythemia vera: is leukocytosis a causative factor? *Blood*. 2009; 114(4):759–763. [PubMed: 19372254]
86. Pearson TC, Wetherley-Mein G. Vascular occlusive episodes and venous haematocrit in primary proliferative polycythaemia. *Lancet*. 1978; 2(8102):1219–1222. [PubMed: 82733]
87. Di Nisio M, Barbui T, Di Gennaro L, et al. The haematocrit and platelet target in polycythemia vera. *Br J Haematol*. 2007; 136(2):249–259. [PubMed: 17156406]
88. Verstovsek S, Kantarjian H, Mesa RA, et al. Safety and efficacy of INCB018424, a JAK1 and JAK2 inhibitor, in myelofibrosis. *N Engl J Med*. 2010; 363(12):1117–1127. [PubMed: 20843246]




Figure 1. Algorithm for the investigation and diagnosis of thrombocytosis

ET indicates essential thrombocythemia; FBC, full blood count; MCV, mean cell volume; MPN, myeloproliferative neoplasm; and PV, polycythemia vera.




Figure 2. Isolated thrombocytosis and bone marrow fibrosis in the absence of clinical features to support a diagnosis of primary myelofibrosis

(A) Bone marrow samples obtained at diagnosis from a 54-year-old female patient with thrombocytosis in the absence of additional features of PMF: left, bone marrow aspirate stained withWright-Giemsa showing a large megakryocyte with a hyperlobated nucleus; middle, bone marrow trephine biopsy stained with hematoxylin and eosin showing loose clusters of megakaryocytes containing both large megakaryocytes with hyperlobated nuclei and smaller forms with cloudlike or hyperchromatic nuclei; right, silver-stained bone marrow section showing grade 4 reticulin fibrosis (on 0-4 scale). (B) Blood counts during the course of 54 months from diagnosis showing stabilization of the platelet count and no change in hemoglobin level. Red and blue shaded areas represent the normal range for hemoglobin and platelet count, respectively.

Clinical case:

- 67 year old female presenting with anemia, splenomegaly, leukoerythroblastic blood film, dysplastic megakaryocyte morphology and grade 4 bone marrow fibrosis: diagnosed with PMF (*JAK2* and *MPL* mutation negative).
- Persistent thrombocytosis noted over ten years prior to presentation; iron studies and inflammatory markers repeatedly normal.
- Presentation with PMF preceded by a gradual fall in platelet and hemoglobin levels.
- Findings suggest previously undiagnosed ET with myelofibrotic transformation at presentation




Figure 3. Presentation with myelofibrotic transformation of previously undiagnosed ET
 (A) Platelet and hemoglobin levels during a 10-year period before presentation with PMF in a patient at the age of 67 years; a marked thrombocytosis between 8 and 10 years before diagnosis is followed by a gradual decrease in platelet count and progressive anemia in the absence of iron deficiency or inflammation. (B) At clinical presentation, left, Wright-Geimsa–stained blood film showing leukoerythroblastosis and tear-drop red cells; middle, hematoxylin and eosin–stained bone marrow trephine biopsy showing clusters of dysplastic megakaryocytes; and right, silver-stained bone marrow trephine biopsy showing grade 4 reticulin fibrosis (on 0-4 scale). Red and blue shaded areas represent the normal range for hemoglobin and platelet count, respectively.




Figure 4. Distribution of hematocrit level in *JAK2* V617F-positive disease
(A) Diagrammatic representation of hemoglobin levels in patients with *JAK2* V617F-negative ET, V617F-positive ET and V617F-positive PV, showing mean hemoglobin levels for patients with V617F-positive and negative ET (from Campbell et al⁷) and V617F-positive PV (from Cambridge cohort); hemoglobin levels in the mid-range will include patients with both ET and PV. (B) Hematocrit levels at diagnosis from a cohort of patients attending the Cambridge MPN clinic and diagnosed with *JAK2* V617F-positive ET or PV, showing considerable overlap in hematocrit between ET and PV in both male and female patients.

Table 1**Causes of thrombocytosis****Myeloid malignancy**

Essential thrombocythemia
 Polycythemia vera
 Primary myelofibrosis
 Chronic myeloid leukemia
 Refractory anemia with ringed sideroblasts and thrombocytosis
 Myelodysplastic syndrome associated with isolated del(5q)

Reactive (secondary) thrombocytosis

Blood loss or iron deficiency
 Infection or inflammation
 Disseminated malignancy
 Drug effect (vincristine, epinephrine, all-trans-retinoic acid)
 Hyposplenism or congenital absence of spleen
 Hemolytic anemia

Familial thrombocytosis

Mutations in *TPO*, *MPL*, or unknown genes

Spurious thrombocytosis

Cryoglobulinemia
 Cytoplasmic fragmentation accompanying myeloid or lymphoid neoplasia
 Red cell fragmentation

Table 2

Criteria for the diagnosis of ET

WHO 2008	BCSH 2010
Requires A1-A4	Requires A1-A3 or A1 + A3-A5
A1: Sustained platelet count >450 × 10 ⁹ /L	A1: Sustained platelet count >450 × 10 ⁹ /L
A2: Bone marrow showing increased numbers of enlarged, mature megakaryocytes; no significant increase of left-shift of granulopoiesis or erythropoiesis*	A2: Presence of an acquired pathogenetic mutation (eg, in <i>JAK2</i> or <i>MPL</i>)
A3: Not meeting WHO criteria for PV, PMF, CML, MDS, or other myeloid neoplasm	A3: No other myeloid malignancy, especially PV, PMF, CML, or MDS
A4: Acquired mutation or clonal marker or no reactive cause for thrombocytosis	A4: No reactive cause for thrombocytosis and normal iron stores
	A5: Bone marrow aspirate and trephine biopsy showing increased megakaryocyte numbers displaying a spectrum of morphology with predominant large megakaryocytes with hyperlobated nuclei and abundant cytoplasm.

BCSH indicates British Committee for Standards in Haematology; CML, chronic myeloid leukemia; ET, essential thrombocythemia; MDS, myelodysplastic syndromes; MPN, myeloproliferative neoplasm; PMF, primary myelofibrosis; PV, polycythemia vera; and WHO, World Health Organization.

* Increased reticulin fibrosis excludes a diagnosis of ET

Table 3

Criteria for the diagnosis of myelofibrosis

Primary myelofibrosis	Myelofibrotic transformation of ET or PV
Requires A1 + A2 and any 2 B criteria	Requires A1 + A2 and any 2 B criteria
A1: Bone marrow fibrosis 3 (on 0-4 scale)	A1: Bone marrow fibrosis 3 (on 0-4 scale)
A2: Pathogenetic mutation (eg, in <i>JAK2</i> or <i>MPL</i>) or absence of both BCR-ABL1 and reactive causes of bone marrow fibrosis	A2: Previous diagnosis of ET or PV
B1: Palpable splenomegaly	B1: New palpable splenomegaly or increase in spleen size of 5cm
B2: Unexplained anemia	B2: Unexplained anemia with 2 g/dL decrease from baseline hemoglobin
B3: Leukoerythroblastic blood film	B3: Leukoerythroblastic blood film
B4: Teardrop-shaped red cells	B4: Teardrop-shaped red cells
B5: Constitutional symptoms*	B5: Constitutional symptoms*
B6: Histological evidence of extramedullary hematopoiesis	B6: Histological evidence of extramedullary hematopoiesis

Criteria adapted from Campbell and Green.¹

ET indicates essential thrombocythemia; and PV, polycythemia vera.

* Drenching night sweats, weight loss >10% over 6 months, unexplained fever (>37.5°C) or diffuse bone pains.

Table 4

Risk stratification for patients with essential thrombocythemia

High risk	No high-risk features	
	Low risk	Intermediate risk
Age > 60 y	Age < 40 y	Age 40-60 y
Prior thrombosis		
Platelets >1500 × 10 ⁹ /L		

Table 5

Choice of cytoreductive agent in essential thrombocythemia

Age group	First line	Second line
< 40 y	Interferon	Hydroxycarbamide Anagrelide
40-75 y	Hydroxycarbamide	Interferon Anagrelide
> 75 y	Hydroxycarbamide	Anagrelide Pipobroman Busulphan Radioactive phosphorus